Home Alzheimer’s Disease Phase III ASCENT Study of Metastatic TNBC Halted Due to Compelling Efficacy

Phase III ASCENT Study of Metastatic TNBC Halted Due to Compelling Efficacy

The phase III confirmatory ASCENT study will be halted due to compelling evidence of efficacy, according to Immunomedics, the company leading the study.1

The decision was based on the unanimous recommendation by an independent data safety monitoring committee (DSMC) during its routine review of the ASCENT study. 

ASCENT is designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a phase II study of heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoint for the study is progression-free survival, and secondary endpoints include overall survival and objective response, among others.

“It is my distinct honor to have served as Chairperson of the independent DSMC for this important study,” Julie R. Gralow, MD, Jill Bennett Endowed Professor of Breast Cancer at the University of Washington…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments